Aug 18, 2025
FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results
Aug 14, 2025
Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results
Jul 08, 2025
Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones
Jul 01, 2025
Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions
May 09, 2025
Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results
Mar 25, 2025
Soligenix Announces Publication Demonstrating CiVax(TM) Booster Induces Rapid Broad Protection Against COVID-19 Variants
Mar 21, 2025
Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results
Feb 04, 2025
Soligenix to Present at BIO CEO & Investor Conference
Jan 14, 2025
HyBryte(TM) Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
Dec 16, 2024
Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte(TM) for the Treatment of Cutaneous T-Cell Lymphoma
Dec 02, 2024
HyBryte(TM) Clinical Results Demonstrate Continued Improvement Post-Treatment
Nov 14, 2024
Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease
Nov 08, 2024
Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results
Oct 22, 2024
Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin
Oct 16, 2024
Soligenix Invited to Present at Upcoming Investor Conferences
Oct 07, 2024
HyBryte(TM) Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference
Oct 03, 2024
Soligenix Announces Partnership with Sterling Pharma Solutions
Sep 16, 2024
Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024
Sep 03, 2024
Soligenix Receives European Patent for Improved Production of Synthetic Hypericin
Jul 09, 2024
Expanded HyBryte(TM) Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma